within Pharmacolibrary.Drugs.ATC.C;

model C08CA09
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0009166666666666666,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.17,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600,            
    Vdp             = 0.66,
    k12             = 120,
    k21             = 120
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08CA09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lacidipine is a dihydropyridine calcium channel blocker used primarily for the treatment of hypertension. It acts by relaxing vascular smooth muscle and reducing peripheral resistance. It is approved and used clinically in several countries for the management of high blood pressure.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dosing.</p><h4>References</h4><ol><li><p>Da Ros, L, et al., &amp; Milleri, S (2003). Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. <i>Clinical pharmacokinetics</i> 42(1) 99–106. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342010-00004&quot;>10.2165/00003088-200342010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12489980/&quot;>https://pubmed.ncbi.nlm.nih.gov/12489980</a></p></li><li><p>McCormack, PL, &amp; Wagstaff, AJ (2003). Lacidipine: a review of its use in the management of hypertension. <i>Drugs</i> 63(21) 2327–2356. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363210-00008&quot;>10.2165/00003495-200363210-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14524737/&quot;>https://pubmed.ncbi.nlm.nih.gov/14524737</a></p></li><li><p>Kataria, D, et al., &amp; Ali, A (2022). Formulation of Lipid-Based Nanocarriers of Lacidipine for Improvement of Oral Delivery: Box-Behnken Design Optimization, . <i>Assay and drug development technologies</i> 20(1) 5–21. DOI:<a href=&quot;https://doi.org/10.1089/adt.2021.084&quot;>10.1089/adt.2021.084</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34978917/&quot;>https://pubmed.ncbi.nlm.nih.gov/34978917</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08CA09;
